Recently, the "2023 Top 10 Most Valuable Listed Pharmaceutical Companies for Investment in China" (hereinafter referred to as the "Most Investable List") was announced, with JumpCan Pharmaceutical securing a place on the list due to its strong development quality.
The list was compiled based on a comprehensive evaluation of objective data across industrial, management, and capital dimensions, selecting the top 100 listed pharmaceutical companies as candidates. The final top 10 companies were then identified according to their market value growth rate from 2020 to 2022.
JumpCan Pharmaceutical has maintained robust growth momentum in recent years. In 2022, the company achieved an operating revenue of RMB 8.996 billion, a year-on-year increase of 17.90%. Net profit attributable to shareholders of the listed company reached RMB 2.171 billion, up 26.27% year-on-year, while net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 2.029 billion, reflecting a year-on-year growth of 30.30%. The weighted average return on equity stood at 21.91%.
In recent years, the company has consistently increased its R&D investment, launching nearly 20 new products in both traditional Chinese and Western medicine. Additionally, JumpCan Pharmaceutical has established strategic partnerships with TJ Biopharma, Newsoara Biopharma, and Zenshine Pharmaceuticals, introducing innovative drugs such as innovative fusion protein-based long-acting growth hormone, oral PDE4 (phosphodiesterase 4) inhibitor, drug-targeted digestive protease inhibitor, and polymerase acidic protein (PA) endonuclease inhibitor for treating or preventing influenza. These efforts aim to meet the evolving and diverse medication needs of patients.
Inclusion in this list reflects investors' full recognition of the company's development achievements. JumpCan Pharmaceutical will continue to enhance its core competitiveness, adhering to the "Four-One" value philosophy: "to sustain steady growth for the enterprise, to ensure rising income for our employees, to make meaningful tax contributions to the government, and to fulfill our responsibilities with dedication to both society and shareholders." The company is committed to transforming this honor into momentum for high-quality development and delivering even greater results to give back to society.
